Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
Ocugen announced that Dr. Shankar Musunuri, CEO and Co-Founder, will participate in a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, at the Ritz Carlton in Laguna Niguel, California.
The chat is scheduled for March 13, 2023, at 9 a.m. PDT. Dr. Musunuri will discuss Ocugen's progress and upcoming milestones across its integrated pipeline. Additionally, the leadership team will conduct one-on-one meetings with registered investors during the event. A live video webcast will be available on Ocugen's investor site.
- None.
- None.
MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, California.
Details regarding Ocugen’s fireside chat are as follows:
Event: 35th Annual Roth Conference
Date: Monday, March 13, 2023
Time: 9 a.m. PDT
Location: Healthcare Salon – Salon 5 – The Ritz Carlton, Dana Point, California
Dr. Musunuri will highlight Ocugen’s progress across its integrated pipeline and provide an overview of anticipated short- and long-term milestones. Ocugen’s leadership team will be available for one-on-one meetings with registered investors throughout the event.
A live video webcast of the fireside chat will be available on the events page of the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
IR@ocugen.com
FAQ
When is Ocugen's fireside chat at the Roth Conference?
Who will participate in the fireside chat for Ocugen?
Where is the Roth Conference taking place?
What will Dr. Musunuri discuss during the fireside chat?
Will there be a webcast of the Ocugen fireside chat?
